Hisyn Pharmaceutical

Zhejiang Hisun Pharmaceutical Co., Ltd. is one of China's largest and most prominent pharmaceutical companies, specializing in the development, manufacture, and commercialization of active pharmaceutical ingredients (APIs), generic drugs, and innovative biologics. Founded in 1956 and headquartered in Taizhou, the company has evolved from a traditional chemical manufacturer into a fully integrated biopharmaceutical enterprise with a robust R&D pipeline focused on oncology, immunology, and cardiovascular diseases. Hisun is recognized for its extensive manufacturing capabilities, including large-scale fermentation and advanced biotechnology facilities for monoclonal antibodies and antibody-drug conjugates (ADCs). The company has established numerous international partnerships, most notably a high-profile historical joint venture with Pfizer (Hisun-Pfizer), and continues to be a major player in the global supply of anti-infective and oncology therapeutics.